Results 181 to 190 of about 12,742 (223)
Peri-operative anti-inflammatory drug use and seizure recurrence after resective epilepsy surgery: Target trials emulation. [PDF]
iScienceSzlak L +9 more
europepmc +1 more source
Medication Prescribing Observations in Care Transitions for Incarcerated Patients. [PDF]
Hosp PharmShoulders BR, Maguigan KL, Lemon SJ.
europepmc +1 more source
Estimating risk of reported versus theoretical drug-drug interactions in headaches medicine: an exhaustive comparison between DrugBank and FAERS database for abortive and preventive combinations. [PDF]
J Oral Facial Pain HeadacheKaytser V, Hakkinen I, Dave J, Zhang P.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Epilepsy Research, 2006
Zonisamide (Zonegran), a novel antiepileptic drug (AED) approved recently in Europe as adjunctive therapy for refractory partial seizures in adults, has been used extensively in Japan and the United States. A substantial body of clinical experience has accumulated over a 14-year period, allowing the properties and pharmacologic/clinical profiles of ...
exaly +3 more sources
Zonisamide (Zonegran), a novel antiepileptic drug (AED) approved recently in Europe as adjunctive therapy for refractory partial seizures in adults, has been used extensively in Japan and the United States. A substantial body of clinical experience has accumulated over a 14-year period, allowing the properties and pharmacologic/clinical profiles of ...
exaly +3 more sources
Zonisamide for Migraine Prophylaxis in Refractory Patients [PDF]
Cephalalgia, 2006 Zonisamide, a new antiepileptic drug, has been approved in the US as adjunctive therapy for the treatment of partial seizures in adults.1,2 Chemically a sulfonamide analogue, zonisamide is thought to have several mechanisms of action, including a rate ...
Ashkenazi, Avi +3 more
exaly +3 more sources
CNS Drugs, 2009
Zonisamide, a widely available antiepileptic drug, has been approved in Japan as adjunctive therapy with levodopa for the treatment of previously treated patients with Parkinson's disease. It is an oral 1,2-benzisoxazole-3-methanesulfonamide and is associated with increased striatal dopamine levels in animal models.
Lily P H, Yang, Caroline M, Perry
openaire +3 more sources
Zonisamide, a widely available antiepileptic drug, has been approved in Japan as adjunctive therapy with levodopa for the treatment of previously treated patients with Parkinson's disease. It is an oral 1,2-benzisoxazole-3-methanesulfonamide and is associated with increased striatal dopamine levels in animal models.
Lily P H, Yang, Caroline M, Perry
openaire +3 more sources